Lymphoma, the most common blood cancer lacks better diagnosis and treatment facilities due to lack of information on genetics for this disease, reveals a new study.
An international research effort led by Duke Cancer Institute scientists has been working to better understand the genetic underpinnings of the most prevalent form of this cancer diffuse large B cell lymphoma and how those genes might play a role in patients' responses to therapies.
Hodgkins Lymphoma
Hodgkins lymphoma or Hodgkins disease has the distinction of being the first cancer to be cured by chemotherapy or by radiotherapy.
Advertisement
‘More than 150 genetic mutations play a significant role in diffusing large B cell lymphoma, which can aid in developing new treatments.’
Tweet it Now
The researchers analyzed tumor samples from 1,001 patients who had been diagnosed with diffuse large B cell lymphoma over the past decade. These patients had been treated at 12 institutions around the world.
Using whole exome sequencing, the researchers pinpointed 150 genetic drivers of the disease, many newly identified.
The team then tested to see if there were any correlations between the genes and how well patients had responded to standard therapies.
![Non-Hodgkins Lymphoma]( "Non-Hodgkins Lymphoma")
Non Hodgkins Lymphoma is a cancer that affects the lymph tissues. It is made up of a wide array of subtypes.
The team applied a genome editing technique known as CRISPR to knock out each of thel 20,000 genes in lymphoma cells to identify those that are critical for lymphoma cells to grow.
By assessing the genetic, CRISPR and clinical results, the researchers found several critical genetic links that could help guide treatments. These findings published online in the journal Cell.
"This work provides a comprehensive road map in terms of research and clinical priorities," said Sandeep Davé, M.D., professor of medicine at Duke.
"We have very good data now to pursue new and existing therapies that might target the genetic mutations we identified. Additionally, this data could also be used to develop genetic markers that steer patients to therapies that would be most effective."
Source: Eurekalert
The team then tested to see if there were any correlations between the genes and how well patients had responded to standard therapies.
Non-Hodgkins Lymphoma
Non Hodgkins Lymphoma is a cancer that affects the lymph tissues. It is made up of a wide array of subtypes.
Advertisement
The team applied a genome editing technique known as CRISPR to knock out each of thel 20,000 genes in lymphoma cells to identify those that are critical for lymphoma cells to grow.
By assessing the genetic, CRISPR and clinical results, the researchers found several critical genetic links that could help guide treatments. These findings published online in the journal Cell.
"This work provides a comprehensive road map in terms of research and clinical priorities," said Sandeep Davé, M.D., professor of medicine at Duke.
"We have very good data now to pursue new and existing therapies that might target the genetic mutations we identified. Additionally, this data could also be used to develop genetic markers that steer patients to therapies that would be most effective."
Source: Eurekalert
AIDS-HIV-Cancer
AIDS defining malignancies are cancers that occur in patients with AIDS due to their low immunity.
Advertisement
 Burkitt’s LymphomaBurkitt's lymphoma is a rare type of non-hodgkin's lymphoma that commonly affects children. It usually begins in the abdominal region. | Advertisement
|
Advertisement
Recommended Readings
Latest Cancer News
The combination of the personalized cancer vaccine with ACT led to ovarian cancer control in few patients within a span of three months, stated study results.
Uncovering key kinases in tumor growth and invasion is crucial for improving targeted therapies in advanced-stage colorectal cancer.
The study findings validate metal-enhanced photo-oxidation for future metal-based anticancer drugs.
Mutations in 11 genes are linked to aggressive forms of prostate cancer, which may present novel therapeutic and therapy options.
Improved oral health, as indicated by the count of natural teeth and dental appointments preceding the diagnosis, correlated with enhanced head and neck cancer survival rates.
